José Valentín
García Gutiérrez
Profesor/a Asociado/a en CC. de la Salud
Hospital de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, EspañaPublications en collaboration avec des chercheurs de Hospital de Gran Canaria Dr. Negrin (36)
2024
-
Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia
Frontiers in Oncology, Vol. 14
-
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
Annals of Hematology, Vol. 103, Núm. 10, pp. 4045-4055
-
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
Leukemia
-
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
HemaSphere
-
Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib
Annals of Hematology, Vol. 103, Núm. 11, pp. 4537-4544
-
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia
Leukemia
-
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
American Journal of Hematology
2023
-
Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia
HemaSphere, Vol. 7, Núm. 8, pp. E936
-
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain
Annals of Hematology, Vol. 102, Núm. 2, pp. 447-456
-
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
Cancers, Vol. 15, Núm. 4
-
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE
British Journal of Haematology, Vol. 202, Núm. 5, pp. 942-952
2022
-
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239
-
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer, Vol. 128, Núm. 13, pp. 2441-2448
2021
-
Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia
British Journal of Haematology, Vol. 192, Núm. 6, pp. 988-996
-
Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea
Leukemia, Vol. 35, Núm. 2, pp. 623-627
-
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
Leukemia, Vol. 35, Núm. 5, pp. 1344-1355
2020
-
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158
-
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
Leukemia and Lymphoma, Vol. 61, Núm. 3, pp. 650-659
-
Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes
Journal of Molecular Diagnostics, Vol. 22, Núm. 10, pp. 1217-1224
-
Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis
Annals of Hematology, Vol. 99, Núm. 4, pp. 791-798